# Translational Development Acquisition Corp. (TDACW) — merger/spac_merger [pending]
Source: SEC API (secapi.ai) · situation sit_96d847388658fc232ed2 · retrieved 2026-08-11T15:50:21.929Z

## Overview
On July 27, 2026, Translational Development Acquisition Corp. (TDAC) and Prologium Holding Inc. (ProLogium) entered into a subscription agreement with Naetas Holding Limited, an institutional accredited investor, for a private investment in public equity (PIPE) transaction. Naetas agreed to purchase 5,000,000 Class A ordinary shares of TDAC at $10.00 per share for an aggregate purchase price of $50,000,000, and to receive 5,000,000 warrants at no additional consideration. The warrants will have an exercise price of $11.50 per share, a redemption trigger threshold of $18.00 per share, and a redemption price of $0.01 per warrant. The subscription closing is expected to occur one business day prior to the consummation of the first merger contemplated by the Business Combination Agreement dated May 27, 2026. At the effective time of the first merger, each subscribed share will be cancelled in exchange for one Class A ordinary share of ProLogium, and each subscribed warrant will be converted into one warrant of ProLogium.

## Terms
- Counterparty: Naetas Holding Limited · Deal value: $50.0M · Consideration: cash · Price/share: $10

## Key dates
- Announced 2026-07-27

## Timeline
- 2026-07-27 · 425 (0001104659-26-087089): 425 - Translational Development Acquisition Corp. — On July 27, 2026, Translational Development Acquisition Corp. (TDAC) and Prologium Holding Inc. (ProLogium) entered into a subscription agreement with Naetas Holding Limited, an institutional accredited investor, for a private investment in public equity (PIPE) transaction. Naetas agreed to purchase 5,000,000 Class A ordinary shares of TDAC at $10.00 per share for an aggregate purchase price of $50,000,000, and to receive 5,000,000 warrants at no additional consideration. The warrants will have an exercise price of $11.50 per share, a redemption trigger threshold of $18.00 per share, and a redemption price of $0.01 per warrant. The subscription closing is expected to occur one business day prior to the consummation of the first merger contemplated by the Business Combination Agreement dated May 27, 2026. At the effective time of the first merger, each subscribed share will be cancelled in exchange for one Class A ordinary share of ProLogium, and each subscribed warrant will be converted into one warrant of ProLogium.
  https://www.sec.gov/Archives/edgar/data/1926599/0001104659-26-087089.txt

## Citations
- 0001104659-26-087089 — https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&type=&dateb=&owner=include&count=40&search_text=000110465926087089